Patent Application
20250134421
The present disclosure relates to a device and a method for measuring, by means of a noninvasive measurement method, the concentration of substances that are included in blood flowing through blood vessels of a living body.
To prevent and treat lifestyle-related diseases, it is significant that the states of substances in blood, such as the blood sugar level and blood lipid level, be checked on a daily basis. In particular, for patients with diabetes, which is one of such lifestyle-related diseases, it is required that the concentration of glucose in blood be measured and the blood sugar level be managed on a daily basis in order to prevent complications, and an invasive method in which blood is sampled from a patient to chemically analyze the blood has been conventionally performed.
In contrast, in recent years, a simple noninvasive method has been proposed in which the state of blood in a living body is optically measured without sampling blood. For example, Patent Literature 1 discloses a substance-in-blood concentration measurement device that measures the blood glucose concentration using a noninvasive and simple structure, by emitting high-intensity mid-infrared light to a living body via a waveguide and guiding reflected light of the high-intensity mid-infrared light through the waveguide to a photodetector.
However, there was a problem with the conventional substance-in-blood concentration measurement device disclosed in document 1, in which a waveguide is used, that measurement cannot be performed properly and stably due to a fluctuation in measurement values caused by the depth position of the measurement-target portion that is a measurement target in a living body differing between individuals.
The present disclosure has been made in view of the above problem, and an object thereof is to provide a substance-in-blood concentration measurement device, a substance-in-blood concentration measurement method, and a program that allow accurate measurement to be performed stably regardless of differences between individuals in the depth of the measurement-target portion in a living body.
In order to achieve the above-described object, a substance-in-blood concentration measurement device according to one aspect of the present disclosure is a substance-in-blood concentration measurement device that measures a concentration of a substance in blood included in the blood in a subject portion of a living body, the substance-in-blood concentration measurement device including: a light emission unit that emits a laser beam to a region of the subject portion that includes a measurement-target portion; a photodetector that receives reflected light based on the emitted laser beam and detects an intensity of the reflected light; a first lens that is disposed between the subject portion and the photodetector in a position where the reflected light from a specific region in the subject portion can form a focused image on the photodetector; and a measurement controller that, based on the intensity of the reflected light, measures a concentration of the substance in blood in the specific region as a concentration of the substance in blood in the measurement-target portion, the substance-in-blood concentration measurement device being characterized in that the light emission unit is capable of selectively emitting: a first laser beam for a target measurement that is absorbed by a first substance in blood that is a measurement-target substance; and a second laser beam for a reference measurement that is absorbed by a second substance in blood that is a reference substance.
According to the substance-in-blood concentration measurement device, the substance-in-blood concentration measurement method, and the program pertaining to aspects of the present disclosure, accurate measurement can be performed stably regardless of differences in the measurement target between individuals.
In recent years, a noninvasive substance-in-blood concentration measurement method that does not involve blood sampling has been proposed in order to, inter alia, manage the blood sugar level of diabetes patients on a daily basis.
As illustrated in
However, as mentioned above, experiments by the inventor, etc., revealed that it is difficult to perform measurement properly and stably using the device 1X, in which the noninvasive method is used, because the state of the skin surface of the measurement-target living body, a slight change in the condition of an emitted laser beam, etc., result in a fluctuation in measurement values.
Furthermore, there is a difference among subjects in the depth and position of a portion of the living body inwards of the skin surface that contains blood sugar, which is the substance to be primarily measured, and this can be considered as being a cause of the fluctuation in measurement values.
In order to solve this problem, it would be necessary, for example, to configure the optical system for each individual subject and instance of measurement so as to be suitable for the condition of the subject's body and measurement conditions.
However, a high degree of skill would be required to adjust the optical system appropriately for each individual living body and instance of measurement, and the convenience of the noninvasive method would be impaired to a great extent if such adjustment were to be performed in the measurement of the blood sugar level performed by patients themselves on a daily basis.
In view of this, the inventors, etc., carried out intensive investigation for an optical system structure that would allow accurate measurement to be performed stably in the noninvasive substance-in-blood concentration measurement method regardless of differences between individuals in the depth of the measurement-target portion in a living body and fluctuations in laser-beam emission conditions, and thereby arrived at the following embodiment.
A substance-in-blood concentration measurement device according to at least one embodiment of the present disclosure is a substance-in-blood concentration measurement device that measures a concentration of a substance in blood included in the blood in a subject portion of a living body, the substance-in-blood concentration measurement device including: a light emission unit that emits a laser beam to a region of the subject portion that includes a measurement-target portion; a photodetector that receives reflected light based on the emitted laser beam and detects an intensity of the reflected light; a first lens that is disposed between the subject portion and the photodetector in a position where the reflected light from a specific region in the subject portion can form a focused image on the photodetector; and a measurement controller that, based on the intensity of the reflected light, measures a concentration of the substance in blood in the specific region as a concentration of the substance in blood in the measurement-target portion, the substance-in-blood concentration measurement device being characterized in that the light emission unit is capable of selectively emitting: a first laser beam for a target measurement that is absorbed by a first substance in blood that is a measurement-target substance; and a second laser beam for a reference measurement that is absorbed by a second substance in blood that is a reference substance.
According to this structure, accurate measurement can be performed stably regardless of differences in the measurement target between individuals.
Furthermore, according to another aspect, in any of the above-described aspects, an absorption rate at which the second laser beam is absorbed by the second substance in blood in the reference measurement is higher than an absorption rate at which the first laser beam is absorbed by the first substance in blood in the target measurement.
Furthermore, according to another aspect, in any of the above-described aspects, a concentration of the reference substance in blood is more stable than a concentration of the measurement-target substance in blood.
According to this structure, the accuracy of the measurement of the measurement target can be improved by performing the target measurement after performing the reference measurement for the reference substance.
Furthermore, according to another aspect, in any of the above-described aspects, the measurement controller is capable of measuring, based on emission of the second laser beam, a concentration of the second substance in blood in a state in which the specific region is included in a blood-vessel region in the subject portion, and is capable of measuring, based on emission of the first laser beam, a concentration of the first substance in blood in the specific region as a concentration of the first substance in blood in the measurement-target portion.
According to this structure, the concentration of the first substance in blood can be measured in a state in which the specific region is included in a blood-vessel region in the subject portion.
Furthermore, according to another aspect, in any of the above-described aspects, a depth of the specific region in the living body can be changed by moving the photodetector along an optical path from the subject portion to the photodetector, and a position of the photodetector can be adjusted along the optical path based on a concentration of the second substance in blood so that the specific region is included in a blood-vessel region in the subject portion.
According to this structure, accurate measurement of the concentration of the first substance in blood can be performed stably at all times regardless of differences, between individuals, in the depth-direction position of blood vessels from the skin surface of the subject, by emitting the first laser beam from the light emission unit at a detector position where reflected light from blood vessels was detected and receiving reflected light from the specific region using the detector.
Furthermore, according to another aspect, in any of the above-described aspects, the light emission unit modulates a wavelength of the laser beam to change a type of substance in blood that can be detected. Alternatively, the light emission unit includes an optical transmitter that emits the first laser beam and an optical transmitter that emits the second laser beam.
According to this structure, multiple types of substances in blood can be measured.
Furthermore, according to another aspect, in any of the above-described aspects, the substance in blood is glucose, and a wavelength of the laser beam is a predetermined wavelength selected from a range of 2.5-12 μm, inclusive. Here, a wavelength of the first laser beam is selected from a range of 6.0-12 μm, inclusive.
According to this structure, the concentration of glucose as the first substance in blood can be measured.
Furthermore, according to another aspect, in any of the above-described aspects, the substance in blood is hemoglobin, and a wavelength of the laser beam is a predetermined wavelength selected from a range of 5.0-12 μm, inclusive.
According to this structure, a blood-vessel region in the subject portion of the living body can be detected, and it can be detected whether or not the specific region that is to become the measurement-target portion in regard to the first substance in blood is included in a blood-vessel region in the subject portion.
Furthermore, according to another aspect, in any of the above-described aspects, a second lens that is positioned between the light emission unit and the subject portion in an optical path of the laser beam, and that condenses the laser beam to the region of the subject portion, and a diaphragm that is positioned between the light emission unit and the second lens are included.
According to this structure, a fluctuation in substance-in-blood-concentration measurement results between instances of measurement can be reduced.
Furthermore, according to another aspect, in any of the above-described aspects, a target placement unit with which a surface of the living body is placed into contact is included, wherein a through-hole is opened in the target placement unit within a region of the target placement unit with which the surface of the living body is placed into contact, the laser beam is emitted to the surface of the living body through the through-hole, and the reflected light is received by the photodetector through the through-hole.
According to this structure, the intensity of the laser beam can be improved because total reflection at the surface of the living body can be suppressed, and also because the laser beam emitted from the light emission unit can directly impinge on the surface of the living body.
Furthermore, according to another aspect, in any of the above-described aspects, a target placement unit with which a surface of the living body is placed into contact is included, wherein a recess portion is formed in the target placement unit within a region of the target placement unit with which the surface of the living body is placed into contact, the laser beam passes through the target placement unit and is emitted to the surface of the living body, and the reflected light passes through the target placement unit and is received by the photodetector.
According to this structure, total reflection at the surface of the living body can be suppressed; furthermore, as a result of there being no opening in the target placement unit, dust, dirt, water vapor, etc., can be prevented from entering the atmosphere in which an optical system including the light emission unit, etc., is present, and the target placement unit can thus be provided with a dust-proofing function.
Furthermore, according to another aspect, in any of the above-described aspects, the measurement-target portion is a blood-vessel region in the subject portion that is located inward of the epidermis, and the first lens transfers a region of the measurement-target portion that is irradiated with the laser beam onto a light receiving surface of the photodetector.
According to this structure, compared to a conventional device in which a waveguide is used, a false-signal (noise) component produced by the reflected light being scattered at the skin surface can be reduced, and the S/N ratio in optical measurement can be improved.
According to this structure, the blood glucose concentration can be stably measured because a laser beam having such a wavelength is absorbed by glucose to a greater extent than near-infrared light and has lower transmittance than near-infrared light, allowing only the skin region to be observed.
Furthermore, according to another aspect, in any of the above-described aspects, the substance in blood is lactic acid, and a wavelength of the laser beam is a predetermined wavelength selected from a range of 5.0-12 μm, inclusive. Here, a wavelength of the first laser beam is within a range of −0.05 μm to +0.05 μm, inclusive, from 5.77 μm, 6.87 μm, 7.27 μm, 8.23 μm. 8.87 μm, or 9.55 μm.
According to this structure, the concentration of lactic acid in blood can be measured. Furthermore, according to another aspect, in any of the above-described aspects, within a section from the target placement unit to the photodetector in an optical path from the subject portion to the photodetector, the reflected light propagates through a space except within a section in which the reflected light passes through the first lens, and, within a section from the light emission unit to the target placement unit in an optical path from the light emission unit to the subject portion, the laser beam propagates through a space except within a section in which the laser beam passes through the second lens.
According to this structure, compared to a conventional device in which a waveguide is used, a false-signal (noise) component produced by the reflected light being scattered at the skin surface can be reduced, and the S/N ratio in optical measurement can be improved.
Furthermore, a substance-in-blood concentration measurement method according to at least one embodiment is a substance-in-blood concentration measurement method for measuring a concentration of a substance in blood included in the blood in a subject portion of a living body, the substance-in-blood concentration measurement method including: emitting, from a light emission unit to an irradiation region in the subject portion that includes a measurement-target portion, a first laser beam for a target measurement that is absorbed by a first substance in blood that is a measurement-target substance; forming a focused image on a photodetector from reflected light of the first laser beam reflected from a specific region in the subject portion using a first lens positioned between the subject portion and the photodetector; and performing the target measurement by receiving the reflected light of the first laser beam using the photodetector, and measuring a concentration of the first substance in blood based on the reflected light as a concentration of the first substance in blood in the measurement-target portion, wherein, prior to the target measurement, a reference measurement is performed by: emitting, from the light emission unit to the irradiation region, a second laser beam for the reference measurement that is absorbed by a second substance in blood that is a reference substance; forming a focused image on the photoreceptor from reflected light of the second laser beam reflected from the specific region using the first lens; and receiving the reflected light of the second laser beam using the photodetector, and measuring a concentration of the second substance in blood based on the reflected light as a concentration of the second substance in blood in the measurement-target portion.
According to this structure, a substance-in-blood concentration measurement method can be provided according to which accurate measurement can be performed stably regardless of differences in the measurement target between individuals.
Furthermore, according to another aspect, in any of the above-described aspects, an absorption rate at which the second laser beam is absorbed by the second substance in blood in the reference measurement is higher than an absorption rate at which the first laser beam is absorbed by the first substance in blood in the target measurement.
Furthermore, according to another aspect, in any of the above-described aspects, a concentration of the reference substance in blood is more stable than a concentration of the measurement-target substance in blood.
According to this structure, the accuracy of the measurement of the measurement target can be improved by performing the target measurement after performing the reference measurement for the reference substance having a relatively high absorption rate.
Furthermore, according to another aspect, in any of the above-described aspects, prior to the detection of the concentration of the first substance in blood, by further measuring the concentration of the second substance in blood while changing a position of the photodetector along an optical path from the subject portion to the photodetector, the position of the photodetector is adjusted along the optical path so that the specific region is included in a blood-vessel region in the subject portion.
According to this structure, a method can be provided in which accurate measurement of the concentration of the first substance in blood is performed stably at all times regardless of differences, between individuals, in the depth-direction position of blood vessels from the skin surface of the subject by emitting the first laser beam from the light emission unit at a detector position where reflected light from blood vessels was detected and receiving reflected light from the specific region using the detector.
Furthermore, according to another aspect, in any of the above-described aspects, the first laser beam and the second laser beam are emitted to the irradiation region using: a second lens that is positioned between the light emission unit and the subject portion in an optical path from the light emission unit to the subject portion, and that condenses the first laser beam and the second laser beam to the irradiation region; and a diaphragm that is positioned between the light emission unit and the second lens and that restricts light emitted from the light emission unit.
According to this structure, a fluctuation in substance-in-blood-concentration measurement results between instances of measurement can be reduced.
Furthermore, according to another aspect, in any of the above-described aspects, a surface of the living body is placed into contact with a target placement unit, the first laser beam and the second laser beam are emitted to the surface of the living body through a through-hole opened in the target placement unit, and the reflected light is received by the photodetector through the through-hole.
According to this structure, the intensity of the laser beams can be improved because the laser beams emitted from the light emission unit can directly impinge on the surface of the living body.
Furthermore, a program according to at least one embodiment is a program that causes a computer to execute substance-in-blood concentration measurement processing of measuring a concentration of a substance in blood included in the blood in a subject portion of a living body, wherein the substance-in-blood concentration measurement processing includes: emitting, from a light emission unit to an irradiation region in the subject portion that includes a measurement-target portion, a first laser beam for a target measurement that is absorbed by a first substance in blood that is a measurement-target substance; forming a focused image on a photodetector from reflected light of the first laser beam reflected from a specific region in the subject portion using a first lens positioned between the subject portion and the photodetector; and performing the target measurement by receiving the reflected light of the first laser beam using the photodetector, and measuring a concentration of the first substance in blood based on the reflected light as a concentration of the first substance in blood in the measurement-target portion, wherein, prior to the target measurement, a reference measurement is performed by: emitting, from the light emission unit to the irradiation region, a second laser beam for the reference measurement that is absorbed by a second substance in blood that is a reference substance; forming a focused image on the photodetector from reflected light of the second laser beam reflected from the specific region using the first lens; and receiving the reflected light of the second laser beam using the photodetector, and measuring a concentration of the second substance in blood based on the reflected light as a concentration of the second substance in blood in the measurement-target portion.
According to this structure, a program can be provided that allows accurate measurement to be performed stably regardless of differences in the measurement target between individuals.
A substance-in-blood concentration measurement device 1 according to the present embodiment will be described with reference to the drawings. Here, in this description, the positive and negative directions in the height direction may be respectively referred to as the “upward” and “downward” directions, and a surface facing the positive direction in the height direction and a surface facing the negative direction in the height direction may be respectively referred to as a “front” surface and a “rear” surface. Furthermore, members in the drawings are not necessarily drawn to scale. Furthermore, in this description, numerical ranges indicated using the symbol “−” include the values at both ends of the numerical ranges. Further, only preferred examples of materials, numerical values, etc., are indicated in the present embodiment, and there is no limitation thereto.
The substance-in-blood concentration measurement device 1 (also referred to hereinafter as a “device 1”) is a medical device that noninvasively measures the concentration of a substance in the blood of a living body Ob in a measurement-target portion Mp by emitting a laser beam having a specific wavelength from a light source to the measurement-target portion Mp and detecting the intensity of reflected light from the measurement-target portion Mp. As the laser beam, light of a specific wavelength capable of being absorbed by the substance to be measured is used. When the concentration of the substance in blood is high, the intensity of reflected light reflected from the measurement-target portion Mp decreases due to absorption by the substance; thus, the device 1 measures the concentration of the substance in blood by measuring the intensity of reflected light using a photodetector.
Structures of the elements of the device 1 will be described below.
The target placement unit 10 is a plate-shaped guide member for regulating the measurement-target portion Mp included in a subject portion Mp0 of the living body Ob to a predetermined position and angle that are suitable for measurement when the skin surface of the living body Ob is placed into contact with a front surface 10a of the target placement unit 10. By covering an optical system including the light emission unit 20, etc., with a housing (unillustrated) and providing the target placement unit 10 on the outer-shell portion of the housing, the target placement unit 10 can be made to function as an emission window from which a laser beam L1 is emitted.
The target placement unit 10 is formed from a material such as ZnSe that is transparent with respect to mid-infrared light that is the specific wavelength used for measurement, and may have an anti-reflection coating layer provided on the front surface thereof. A measurement position is marked on the front surface 10a of the target placement unit 10. By placing the living body Ob into contact with the front surface 10a of the target placement unit 10 with a predetermined pressure in a state in which the living body Ob including the measurement-target portion Mp is positioned with respect to the measurement position, the measurement-target portion Mp, which is a portion of the living body that is located inward of the epidermis, such as the dermis for example, can be kept in a state in which the measurement-target portion Mp is separated from the front surface 10a of the target placement unit 10 by a predetermined distance.
Furthermore, the target placement unit 10 is disposed so that the laser beam L1 emitted from the light emission unit 20 enters from a rear surface 10d-side thereof, and the angle of the front surface 10a relative to the light emission unit 20 is regulated so that an incident angle θ of an incident-side optical axis L1 equals a predetermined angle. Here, the incident angle θ indicates the angle of the optical axis L1 with respect to the normal to the front surface 10a of the target placement unit 10, on which the living body Ob is placed.
Alternatively, as illustrated in
In this case as well, similarly to the case in which the opening 10b is provided, an air layer is formed between the front surface 10a of the target placement unit 10 and the living body Ob as a result of the recess portion 10c being provided, and, compared to a case in which the living body Ob is placed into contact with the target placement unit 10, total reflection at the surface of the living body Ob can be suppressed. Furthermore, by providing the recess portion 10c, the living body Ob can be placed into closer contact with the front surface 10a of the target placement unit 10 at portions other than the recess portion. According to the present embodiment, as one example, the thickness of the target placement unit 10 may be approximately 500 μm, the width of the recess portion 10c may be approximately 700 μm, and a depth d1 of the recess portion 10c, or in other words the thickness of the air layer, may be approximately 400 μm.
The light emission unit 20 is a light source that emits a laser beam having a specific wavelength to the living body, i.e., the subject portion Mp0 of the living body Ob. The light emission unit 20 is capable of emitting a laser beam for target measurement (may be referred to hereinafter as a “first laser beam”) that oscillates at a wavelength that is absorbed by a first substance in blood that is the measurement-target substance (may be referred to hereinafter as a “first substance in blood”).
Furthermore, in the device 1, the light emission unit 20 is capable of modulating laser-beam wavelength to selectively emit the laser beam for target measurement and a laser beam for reference measurement (may be referred to hereinafter as a “second laser beam”) that oscillates at a wavelength that is absorbed by a second substance in blood that is a reference substance (may be referred to hereinafter as a “second substance in blood”). Thus, the type of substance in blood that can be detected is changed.
In the present embodiment, as one example, glucose may be adopted, for example, as the first substance in blood that is the measurement-target substance. In such a case, light having a wavelength selected from mid-infrared light is emitted as the laser beam; i.e., as the wavelength oscillated by optical parametric oscillation, mid-infrared light is used due to being a wavelength that is absorbed to a greater extent by glucose than conventionally used near-infrared light, and a predetermined wavelength selected from the range of 2.5-12 μm, inclusive, may be adopted. A predetermined wavelength selected from the range of 6.0-12 μm, inclusive, is more preferable. Specifically, in the present embodiment, the selected wavelength is 9.26 μm. For example, a wavelength within the range of 9.26±0.05 μm (9.21-9.31 μm, inclusive) may be adopted. Alternatively, the wavelength may be selected from within the range of −0.05 μm to +0.05 μm, inclusive, from 7.05 μm, 7.42 μm, 8.31 μm, 8.7 μm, 9.0 μm, 9.57 μm, 9.77 μm, 10.04 μm, or 10.92 μm.
Thus, the glucose concentration in the subject's blood can be measured as the blood sugar level. In this case, it is necessary to measure the glucose concentration in blood vessels in the skin, and mid-infrared light, which does not readily penetrate deeply into the body, is emitted directly to blood vessels (capillary vessels) in the skin. Mid-infrared light has lower transmittance into the body than near-infrared light conventionally used to measure the blood sugar level; thus, by identifying the position of blood vessels in the skin and emitting mid-infrared light thereto, an effect can be obtained that observation of only the blood-vessel portion is possible, in which case the observation is less susceptible to the influence of other body components present deeper in the body. Furthermore, by using mid-infrared light, an effect can also be obtained that the negative influence of overlaps of combination tones and overtones of fundamental vibrations on the measurement is reduced, and glucose can be measured more accurately than with near-infrared light.
On the other hand, as the reference substance (second substance in blood) measured in the reference measurement, a substance in blood satisfying the following is selected. That is, the substance has a higher laser-beam absorption rate than the measurement-target substance and thus has high measurement sensitivity, and the concentration of the substance in blood is very stable, resulting in less fluctuation in measurement results.
That is, the absorption rate at which the laser beam in the reference measurement is absorbed by the reference substance (second substance in blood) is preferably higher than the absorption rate at which the laser beam for target measurement is absorbed by the measurement-target substance (first substance in blood) in the target measurement. Additionally/alternatively, the concentration of the reference substance (second substance in blood) in blood is preferably more stable than the concentration of the measurement-target substance (first substance in blood) in blood.
The accuracy of the measurement of the measurement target can be improved by performing the target measurement after performing the reference measurement for the reference substance having this structure.
In the present embodiment, hemoglobin can be selected as one example of the reference substance (second substance in blood). By detecting hemoglobin in blood vessels, the positions of capillary vessels in the living body can be detected, and the most-suitable position of the measurement-target portion Mp in the subject portion Mp0 of the living body Ob for performing the measurement of the measurement-target substance (first substance in blood) can be specified.
When hemoglobin is adopted as the first substance in blood or the second substance in blood, the laser beam to be emitted for measurement is light having a wavelength selected from mid-infrared light, and the wavelength is a predetermined wavelength selected from the range of 5.0-12 μm, inclusive. Specifically, for example, a wavelength within the range of 8.00±0.1 μm (7.9-8.1 μm, inclusive) may be adopted. Alternatively, the wavelength may be selected from: the range of 5.26-6.76 μm, inclusive; within the range of −0.1 μm to +0.1 μm, inclusive, from 7.17 μm; within the range of −0.1 μm to +0.1 μm, inclusive, from 7.58 μm; the range of 7.58-8.33 μm, inclusive; or within the range of −0.1 μm to +0.1 μm, inclusive, from 8.55 μm.
The light source 21 may include a Q-switched Nd:YAG laser (oscillation wavelength: 1.064 μm) or a Q-switched Yb:YAG laser (oscillation wavelength: 1.030 μm). Thus, the light source 21 can oscillate pulsed pump light L0 having a shorter wavelength than mid-infrared light. For example, the pump light L0 may have a pulse width of approximately 8 ns and a frequency of 10 Hz or higher. Furthermore, because a Q-switched Nd:YAG laser or Yb:YAG laser operates as a passive Q-switch that switches passively using a saturable absorber, the light source 21 can be simplified and reduced in size.
As illustrated in
In the nonlinear optical crystal 223, AgGaS suitable for wavelength conversion is used under phase-matching conditions. The wavelength of the oscillated laser beam L1 can be adjusted by adjusting the type and matching conditions of the nonlinear optical crystal 223. GaSe, ZnGeP2, CdSiP2, LiInS2, LiGaSe2, LiInSe2, LiGaTe2, etc., may be used as the nonlinear optical crystal. The laser beam L1 emitted from the OPO 22 is provided with a repetition frequency corresponding to the pump light L0, e.g., a pulse width of approximately 8 ns, and a high-intensity peak output of 10 W to 1 kW, inclusive, can be realized by the short pulse width.
As a result of the light source 21 and the OPO 22 being used in the light emission unit 20 as described above, the laser beam L1, which has a high intensity that is approximately 103 to 105 times the intensity of a conventional light source such as a quantum cascade laser, can be obtained.
A device in which the wavelength of light emitted by the light emission unit 20 is changed can be realized by either: changing the configuration of the oscillation wavelength of the OPO 22 in the light emission unit 20 and changing the phase matching conditions of the nonlinear crystal 223 in the OPO 22; or changing the OPO 22 to that in which the phase matching conditions of the nonlinear crystal 223 are different.
According to this structure, the blood sugar level can be measured using mid-infrared light having low transmittance into the body.
The light emission unit 20 is electrically connected to the later-described measurement controller 60, and outputs the laser beam L1 based on a control signal from the measurement controller 60.
As illustrated in
The condenser lens 50 is optically designed so that the laser beam L1 emitted from the light emission unit 20 is condensed to a depth corresponding to a portion of the living body located inward of the epidermis, such as the dermis for example. The depth corresponds to the specific region that is to become the measurement-target portion Mp of the living body Ob, which is separated by a predetermined distance from the front surface 10a of the target placement unit 10. The incident angle θ of the laser beam L1 on the specific region that is to become the measurement-target portion Mp is determined by the angle of the light emission unit 20 relative to the front surface 10a of the target placement unit 10 and the refraction angle of the laser beam L1 having entered the target placement unit 10. In the present embodiment, the incident angle θ may be set to 45 degrees or more, and may further be set within the range of 60-70 degrees, inclusive, for example.
Here, a beam splitter (unillustrated) formed from a semi-transmissive mirror may be disposed between the light emission unit 20 and the condenser lens 50 to split a portion of the laser beam L1 as a reference signal, and the change in intensity of the laser beam L1 may be detected using a photodetector for monitoring (unillustrated) and be used in detection-signal normalization processing by the photodetector 30. This enables the output of the photodetector 30 to be compensated based on the change in intensity of the laser beam L1.
The laser beam L1 having passed through the condenser lens 50 passes through the target placement unit 10 and enters the living body Ob, where the laser beam L1 passes through the epithelial interstitial tissue of the living body to be scattered or diffusely reflected. The reflected light L2 so produced passes through the target placement unit 10 once again and is emitted toward the photodetector 30.
The diaphragm 80 is disposed in a section between the light emission unit 20 and the condenser lens 50 of the optical path Op1 of the laser beam L1 from the light emission unit 20 to the subject portion Mp0 of the living body Ob. The diaphragm 80 is formed from a light-blocking plate-shaped member, and an opening 80a (aperture) is opened in the center portion thereof.
The center of the opening 80a is aligned with the optical axis of the laser beam L1. Furthermore, the beam diameter of the laser beam L1 may be restricted to approximately one third by the opening 80a, for example. Furthermore, the diaphragm 80 may be disposed at a position where the distance between the condenser lens 50 and the light emission unit 20 is internally divided to a:b, where 1/f=1/a+1/b holds true, and f is the focal length of the condenser lens 50.
By providing the diaphragm 80 between the light emission unit 20 and the condenser lens 50 in the optical path Op1 in such a manner, the fluctuation in the emission position of the laser beam L1 emitted to the living body Ob can be reduced.
The imaging lens 40 is optically designed such that an image Im1 of the specific region corresponding to the measurement-target portion Mp in the subject portion Mp0 is diffusely reflected, and the image Im1 becoming the reflected light L2 is imaged as a focused image Im2 on the screen 30a of the photodetector 30 by the imaging lens 40.
In the present embodiment, a distance Op21 between the center of the imaging lens 40 and the specific region (measurement-target portion Mp) of the living body Ob and a distance Op22 between the screen 30a of the photodetector 30 and the center of the imaging lens 40 are equivalent. Thus, a positional relationship is realized such that the image Im1 at a depth corresponding to the specific region (measurement-target portion Mp) in the subject portion Mp0 irradiated with mid-infrared light is transferred onto the screen 30a of the photodetector 30 as the image Im2 of equivalent size.
Here, for example, the specific region (measurement-target portion Mp) is preferably located in a portion of the living body that is located inward of the epidermis (may be referred to hereinafter as a “a portion of the living body inwards of the skin surface” or “an inwards portion of the living body”), such as the dermis for example. Here, the distances Op21 and Op22 may both be 2F, where F is the focal length of focal points Fp of the imaging lens 40.
However, the lengths of the distances Op21 and Op22 are not limited to those described above; the factors applied to the distances Op21 and Op22 may be set so that the image Im1 irradiated with mid-infrared light fits precisely in the screen 30a of the photodetector 30, and an imaging lens 40 achieving such factors may be configured.
The angle of incidence of the reflected light L2 on the imaging lens 40 is determined by the angle of the imaging lens 40 relative to the front surface 10a of the target placement unit 10 and the refraction angle of the reflected light L2 emitted from the target placement unit 10. In the present embodiment, the incident angle may be set to 0-40 degrees, inclusive, and more preferably 20-30 degrees, inclusive, for example.
In the substance-in-blood concentration measurement device 1, in a state in which the second laser beam for reference measurement is emitted from the light emission unit 20, the detector 30 is moved along the optical path Op2 from the subject portion Mp0 to the photodetector 30 to change the distance of the photodetector 30 from the imaging lens 40. Thus, as illustrated in
The photodetector 30 is a near-infrared/mid-infrared sensor that receives reflected light from the specific region (measurement-target portion Mp) that is based on the emitted laser beam L1, and detects the intensity of the reflected light. The photodetector 30 outputs an electric signal corresponding to the intensity of the received reflected light. For example, as the photodetector 30, a single-element infrared sensor that outputs the intensity of the reflected light as a one-dimensional voltage value may be used.
In the substance-in-blood concentration measurement device 1, the photodetector 30 can receive reflected light having sufficiently high intensity relative to background light as a result of the intensity of the emitted laser beam L1 being increased by the light emission unit 20 and the reflected light reflected from the measurement-target portion Mp being imaged on the photodetector 30 by the imaging lens 40; thus, a high signal-to-noise (S/N) ratio is realized and measurement can be performed with high accuracy. Because the laser beam L1 and the reflected light L2 are monochromatic and have high intensity as discussed above, the photodetector 30 only needs to perform processing of detecting light intensity, and does not need to execute multivariate analysis, spectrum analysis, etc., based on wavelength sweeping as in a photoacoustic optical method in which a quantum cascade laser is used. Thus, the accuracy required in the detection is relaxed, and the easily usable electronic cooling method, etc., can also be used.
Note that, as the photodetector 30, an HgCdTe infrared detector cooled with liquid nitrogen may be used, for example. In this case, the light intensity of the reflected light L2 can be detected with a higher S/N ratio by cooling the photodetector 30 to approximately 77 K using liquid nitrogen.
The photodetector 30 is electrically connected to the later-described measurement controller 60, and, based on a control signal from the measurement controller 60, outputs the intensity of received reflected light to the measurement controller 60 as a one-dimensional voltage value.
The movable mechanism 71 is a linear transportation mechanism that can reversibly move the detector 30 along the optical path Op2 from the subject portion Mp0 to the photodetector 30. As the movable mechanism 71, a general-purpose linear transportation mechanism such as a linear motor, a ball screw, or a rack-and-pinion mechanism can be used. The movable mechanism 71 is electrically connected to the later-described measurement controller 60, and, based on a control signal supplied from the measurement controller 60, transports the detector 30 to a predetermined position.
The measurement controller 60 is electrically connected to the light emission unit 20, the photodetector 30, and the movable mechanism 71: The circuitry drives the light source 21 of the light emission unit 20 to cause the light source 21 to oscillate the pulsed pump light L0, and detects the light intensity of the reflected light L2 based on an output signal from the photodetector 30 to calculate the concentration of a substance in blood in the specific region of the subject portion Mp0.
Also, the output from the photodetector for monitoring may be input to the measurement controller 60, and, even if the intensity of the laser beam L1 emitted from the light emission unit 20 changes, the measurement controller 60 may calculate the concentration of a substance in blood while compensating for the influence of the change in the intensity of the laser beam L1 by normalizing the output from the photodetector 30 using the output from the photodetector for monitoring, as described above.
Furthermore, the measurement controller 60 outputs a control signal to the movable mechanism 71 to drive the movable mechanism 71 and transport the detector 30 along the optical path Op2 to a predetermined position.
The measurement controller 60 executes the later-described substance-in-blood concentration measurement processing based on a predetermined program and executes the above-described processing, such as the transportation of the detector 30, the emission of the laser beam L1 from the light emission unit 20, and the calculation of the concentration of a substance in blood based on a signal from the photodetector 30.
An improvement in S/N ratio during measurement achieved by the optical system in the device 1 will be described.
However, in the device 1, a focused image is formed by the imaging lens 40 on the screen 30a of the photodetector 30 mainly from the reflected light component (Im11) among these reflected light components (Im11, Im12), which is from the specific region (measurement-target portion Mp) in the inwards portion of the living body.
The reflected light component (Im12) from the skin surface enters the imaging lens 40; however, because the angle of incidence of the reflected light component (Im12) on the imaging lens 40 is different from that of the reflected light component (Im11) reflected in the inwards portion of the living body, the reflected light component (Im12) is guided to the outside of the area of the screen 30a of the photodetector 30. Otherwise, even if the reflected light component (Im12) is guided to within the area of the screen 30a of the photodetector 30, the reflected light component (Im12) is not focused (is blurred). Thus, the light amount thereof decreases and the signal intensity detected by the photodetector 30 decreases.
Due to this, the reflected light component (Im12) from the skin surface, which is detected as noise, does not affect the optical measurement much.
That is, in the device 1, the reflected light component (Im11) from the specific region (measurement-target portion Mp) that is to be mainly measured and located in the portion of the living body inwards of the skin surface forms a focused image on the screen 30a of the photodetector 30 and is reflected in the optical measurement by the photodetector 30; thus, a measurement result that is highly correlated with a blood-sugar-level measurement result based on self-monitoring-of-blood-glucose (SMBG) and that has high reproducibility can be obtained.
In such a manner, a false-signal (noise) component produced by reflected light scattered at the skin surface can be reduced and the S/N ratio in optical measurement can be improved with the device 1, compared to the conventional device 1X, in which waveguides are used.
An improvement in measurement accuracy based on the detection of a blood-vessel region in the subject portion Mp0 using the optical system in the device 1 will be described.
As illustrated in
The two-dimensional image-capturing means 71A is a two-dimensional infrared image-capturing element array in which a plurality of light receiving elements capable of detecting mid-infrared light are arranged in a matrix on a light receiving surface 71Aa. As illustrated in
According to this structure, in the substance-in-blood concentration measurement device according to the comparative example, the process of adjusting the length of the optical path from the specific region to the photodetector 30 so that the reflected light from the specific region that is to become the measurement-target portion Mp forms an image on the photodetector 30 can be performed by replacing the photodetector 30 with the two-dimensional image-capturing means 71A, and thus the adjustment of optical-path length can be performed easily.
On the other hand,
As illustrated in
According to this structure, a function is realized of changing the position of the specific region in the subject portion Mp0 from which the reflected light forming an image on the screen 30a of the detector 30 is produced. Here, the specific region is the focus region in the subject portion Mp0 where the imaging lens 40 is in focus with. This function allows the position of the photodetector 30 for measuring the measurement-target substance (first substance in blood) to be adjusted to a state in which focus is on a capillary-vessel position in the living body.
That is, the device 1 can stably measure whether or not an image Im11 based on reflected light from a blood vessel that is to become the measurement-target portion Mp is imaged as a focused image on the photodetector 30 by the reference measurement. That is, the device 1 can stably measure whether or not the image Im11 is imaged as a focused image on the photodetector by, in a state in which the laser beam for reference measurement (second laser beam) L1 is emitted, receiving the reflected light L2 reflected from the specific region and measuring the concentration of the reference substance (second substance in blood). The reference substance (second substance in blood) is characterized in that the reference substance (second substance in blood) has a higher laser-beam absorption rate than the measurement-target substance (first substance in blood) and/or the concentration in blood of the reference substance (second substance in blood) is more stable than that of the measurement-target substance (first substance in blood).
Accordingly, reflected light from a blood vessel can be detected based on reflected light produced from the laser beam for target measurement (first laser beam) while gradually moving the detector 30.
As illustrated in
By emitting the laser beam for target measurement (first laser beam) from the light emission unit 20 and receiving the reflected light from the specific region using the detector 30 at a position of the detector 30 where reflected light from a blood vessel was detected in the above-described manner, the concentration of the measurement-target substance (first substance in blood) can be measured in a state in which the specific region is included in a blood-vessel region of the subject portion (see the annotation in
Next, as a verification experiment, the concentration in blood of glucose, which is the measurement-target substance, was measured using the example of the device 1.
As illustrated in
Note that, in the results illustrated in
Furthermore, according to the SMBG measurement results and laser measurement results for individual subjects, the subjects for which the amount by which the laser-intensity I/O ratio changes relative to measurement depth is greater have higher SMBG-based blood sugar measurement values, and it could thus be understood that there is a relation of dependence between the blood sugar level value and the change in laser reception intensity.
Thus, accurate measurement can be performed stably at all times regardless of the state of the skin surface, which differs between subjects and instances of measurement, and differences between individuals in the position of blood vessels in the depth direction from the skin surface. Furthermore, an effect can be obtained that measurement can be performed also on targets having thick skin by changing the light-receiving-side optical path length L by adjusting photodetector position.
An improvement, by the optical system in the device 1, of a fluctuation in substance-in-blood-concentration measurement results has been examined.
As illustrated in
On the other hand, in a comparative example of the device 1, the collimated laser beam L1 is condensed to the photodetector PD by the condenser lens 50, as illustrated in
As illustrated in
That is, in the device 1, in which the diaphragm 80 was provided in the optical path from the light emission unit 20 to the photodetector PD, a remarkable improvement was observed within measurement events and between events compared to the comparative example, in which the diaphragm 80 was not provided.
It can be considered that this is because, due to the provision of the diaphragm 80, beam diameter was made uniform regardless of individual differences in the size of the portion of the light emission unit 20 from which the laser beam L1 is emitted, and the center of the optical axis of the laser beam L1 was aligned with the optical axis of the condenser lens 50.
A reduction of measurement fluctuation achieved by the optical system of the device 1 measuring the inside of the skin of the living body Ob has been examined.
Using the device 1, the concentration of the reference substance (second substance in blood) as measured by the photodetector 30 was measured in a comparative example in which the position of the photodetector 30 was adjusted so that the specific region is set to the skin surface of the living body Ob and an example of the device 1 in which the position of the photodetector 30 was adjusted so that the specific region is set in the skin of the living body Ob.
As illustrated in
Furthermore, as illustrated in
Furthermore, by emitting the laser beam for target measurement (first laser beam) from the light emission unit 20 at an in-plane-direction measurement position where reflected light indicating a blood-vessel region was detected, and receiving reflected light at the measurement position using the detector 30, the concentration of the measurement-target substance can be measured in a state in which the in-plane-direction measurement position is included in a blood-vessel region in the subject portion.
Thus, accurate measurement can be performed stably at all times regardless of differences between individuals in in-plane-direction positions of blood vessels, which differs between subjects and instances of measurement.
An outline of operation of the substance-in-blood concentration measurement device 1 will be described with reference to
In
Steps S21 and S22 are steps for the target measurement, in which the concentration of the measurement-target substance (first substance in blood) is measured in a state in which the specific region is included in a blood-vessel region in the subject portion.
In
Next, the reference measurement is performed in steps S11 and S12. First, based on a control signal, the measurement controller 60 emits the laser beam for reference measurement (second laser beam) from the light emission unit 20 to the specific region (step S11), measures the concentration of the reference substance (second substance in blood) in the specific region using the photodetector 30 (step S12), and determines whether or not the measured concentration of the reference substance is higher than or equal to a reference value (step S13).
Processing is terminated if the measured concentration is not higher than or equal to the reference value in step S13 (step S13: No), whereas, the concentration of the measurement-target substance (first substance in blood) is measured in steps S21 and S22 if the measured concentration is higher than or equal to the reference value in step S12 (step S13: Yes) because it is determined that the specific region is included in a blood-vessel region in the subject portion. Specifically, the laser beam for target measurement (first laser beam) is emitted from the light emission unit 20 to the specific region (step S21), a measurement of the concentration of the measurement-target substance in the specific region (target measurement) is performed using the photodetector 30 to output a measurement result (step S22), and processing is terminated.
(Operation for Adjusting Photodetector Position along the Optical Path)
In
Steps S21 and S22 are steps for the target measurement, in which the concentration of the measurement-target substance (first substance in blood) is measured in a state in which the specific region is included in a blood-vessel region in the subject portion. Processing that is the same as processing in
In
Next, it is determined whether or not the photodetector 30 is in an end position (step S14). If the photodetector 30 is not in the end position (step S14: No), the position of the photodetector 30 is moved slightly (step S15), and processing returns to step S11, whereas, if the photodetector 30 is in the end position (step S14: Yes), processing proceeds to step S16, it being regarding that the measurement of the concentration of the reference substance in the specific region has been performed at all photodetector positions.
In step S16, based on the results of the measurement of the concentration of the reference substance in the specific region at all photodetector positions, the photodetector is moved to an optimal position where the result indicating the highest reference-substance concentration was obtained. It is inferred that the specific region is included in a blood-vessel region in the subject portion at the optimal position.
Next, the concentration of the measurement-target substance (first substance in blood) is measured in steps S21 and S22. Specifically, the laser beam for target measurement (first laser beam) is emitted from the light emission unit 20 to the specific region (step S21), a measurement (target measurement) of the concentration of the measurement target in the specific region is performed using the photodetector 30 to output a result (target measurement; step S22), and processing is terminated.
In
Steps S21 and S22 are steps for the target measurement, in which the concentration of the measurement-target substance (first substance in blood) is measured in a state in which the emission position is included in a blood-vessel region in the in-plane direction in the subject portion.
Processing that is the same as processing in
In
Next, it is determined whether or not the emission position is in an end position (step S14). If the emission position is not in the end position (step S14: No), the emission position is changed (step S15A), and processing returns to step S11, whereas, if the emission position is in the end position (step S14: Yes), processing proceeds to step S16A, it being regarded that the measurement of the concentration of the reference substance in the specific region has been performed at all emission positions.
In step S16A, based on the results of the measurement of the concentration of the reference substance (second substance in blood) in the specific region at all emission positions, the emission position is changed to an optimal position where the result indicating the highest reference-substance concentration was obtained. It is inferred that the emission position is included in a blood-vessel region in the in-plane direction of the subject portion at the optimal position.
Next, the concentration of the measurement-target substance (first substance in blood) is measured in steps S21 and S22. Specifically, the laser beam for target measurement (first laser beam) is emitted from the light emission unit 20 to the specific region (step S21), a measurement of the concentration of the measurement target in the specific region is performed using the photodetector 30 to output a result (target measurement; step S22), and processing is terminated.
As described above, a substance-in-blood concentration measurement device 1 according to the embodiment is a substance-in-blood concentration measurement device 1 that measures a concentration of a substance in blood included in the blood in a subject portion Mp0 of a living body Ob, the substance-in-blood concentration measurement device 1 including: a light emission unit 20 that emits a laser beam to a region of the subject portion that includes a measurement-target portion Mp; a photodetector 30 that receives reflected light L2 based on the emitted laser beam L1 and detects an intensity of the reflected light; a first lens 40 that is disposed between the subject portion Mp0 and the photodetector 30 in a position where the reflected light L2 from a specific region Mp in the subject portion Mp0 can form a focused image on the photodetector 30; and a measurement controller 60 that, based on the intensity of the reflected light L2, measures a concentration of the substance in blood in the specific region Mp as a concentration of the substance in blood in the measurement-target portion Mp, the substance-in-blood concentration measurement device 1 being characterized in that the light emission unit 20 is capable of selectively emitting: a laser beam for target measurement that is absorbed by a measurement-target substance (first substance in blood); and a laser beam for reference measurement (second laser beam) that is absorbed by a reference substance (second substance in blood).
Furthermore, an absorption rate at which the laser beam in the reference measurement (second laser beam) is absorbed by the second substance in blood may be higher than an absorption rate at which the laser beam for target measurement is absorbed by the first substance in blood in the target measurement. Furthermore, a concentration of the reference substance in blood may be more stable than a concentration of the measurement-target substance in blood.
Furthermore, the measurement controller 60 may be capable of measuring, based on emission of the laser beam for reference measurement (second laser beam), a concentration of the reference substance (second substance in blood) in a state in which the specific region Mp is included in a blood-vessel region in the subject portion; and may be capable of measuring, based on emission of the laser beam for target measurement, a concentration of the measurement-target substance (first substance in blood) in the specific region Mp.
Furthermore, a depth of the specific region Mp in the living body may be changed by moving the photodetector 30 along an optical path Op2 from the subject portion Mp0 to the photodetector 30, and a position of the photodetector 30 may be adjusted along the optical path Op2 based on a concentration of the reference substance (second substance in blood) so that the specific region Mp is included in a blood-vessel region in the subject portion Mp0.
According to such structures, accurate measurement can be stably performed regardless of differences between individuals in the depth of the measurement-target portion in the living body and the fluctuation in laser-beam emission conditions. Thus, a noninvasive and simple measurement method can be realized by eliminating work for adjusting the optical system appropriately for each individual living body and instance of measurement in the measurement of the blood sugar level performed by patients themselves on a daily basis.
Up to this point, specific structures of the present disclosure have been described taking embodiments as examples, but the present disclosure is not limited by the above embodiments in any way, except for essential characteristic constituent elements thereof. For example, an embodiment that can be obtained by applying various modifications to the embodiments, and an embodiment that can be realized by combining constituent elements and functions in the embodiments within the scope of the present invention are also included in the present disclosure.
(1) In the embodiments, an embodiment has been described taking glucose as an example of the measurement-target substance (first substance in blood) to be detected by the substance-in-blood concentration measurement device. However, components in blood that can be detected by the substance-in-blood concentration measurement device according to the present disclosure are not limited to the above, and the device can be widely used for other detection targets by changing the wavelength of the laser beam L1 emitted by the light emission unit 20 according to the type of component in blood.
For example, the wavelength of the laser beam L1 emitted by the light emission unit 20 may be 8.23±0.05 μm (8.18-8.28 μm, inclusive), and the component in blood may be lactic acid. Alternatively, the wavelength may be within the range of −0.05 μm to +0.05 μm, inclusive, from 5.77 μm, 6.87 μm, 7.27 μm, 8.87 μm, or 9.55 μm. The inventor, etc., have confirmed through experimentation that lactic-acid concentration measurement values obtained by the photodetector when the wavelength of light emitted by the light emission unit 20 is set to 8.23 μm are generally correlated with lactic-acid-value measurement results obtained by SMBG.
(2) In the embodiments, an embodiment has been described taking hemoglobin as an example of the reference substance (second substance in blood) detected in the reference measurement. However, the reference substance according to the present disclosure is not limited to the above, and application to other reference substances is possible by changing the wavelength of the laser beam L1 emitted by the light emission unit 20 according to the type of component in blood to be used as the reference substance.
(3) In the embodiments, the wavelength of the oscillated laser beam L1 can be switched and adjusted by adjusting the type and matching conditions of the nonlinear optical crystal 223 in the OPO 22.
However, a device that can measure a plurality of types of components in blood may be realized by adopting, in the light emission unit 20, a device structure such that a plurality of OPOs 22 can be selectively used, and laser beams L1 of a plurality of wavelengths can be selectively emitted. Light emitted from the light source 21 may be switchingly made to enter the plurality of OPOs emitting light of different wavelengths so that light of different wavelengths is selectively emitted from the OPOs, and the reference measurement and the main measurement of the measurement target can be selectively performed using the different wavelengths.
Alternatively, a plurality of light emission units 20 emitting light of different wavelengths may be used, and the light from two light emission units 20 may be selectively emitted as the laser beam L1 using an optical coupler, a mirror, etc. Differing from a structure in which optical systems having different optical path width, thickness, etc., are used depending on the wavelengths of light, this enables the same optical system formed from the condenser lens 50, the target placement unit 10, the imaging lens 40, and the photodetector 30 capable of detecting mid-infrared light to be used as an optical system for a plurality of components in blood, for example.
(4) In the embodiments, in regard to the light emission unit 20, the first laser beam for target measurement and the second laser beam for reference measurement have different wavelengths. However, as long as the first laser beam for target measurement and the second laser beam for reference measurement are respectively absorbed by the measurement-target substance and the reference substance, an emission condition other than wavelength may be varied between the first laser beam and the second laser beam. For example, the intensity of light emitted from the emission unit may be varied between the first laser beam and the second laser beam.
(5) In the embodiments, the measurement-target substance and the reference substance are different substances in blood. However, the reference measurement may be performed using the same substance as the measurement-target substance.
(6) In the embodiments, an embodiment of a substance-in-blood concentration measurement device has been described taking as an example an optical system including the imaging lens 40 between the measurement-target portion Mp and the photodetector 30. However, as long as the substance-in-blood concentration measurement device according to the present disclosure forms an image from the reflected light L2 reflected from the measurement-target portion Mp of the living body Ob on the photodetector 30, the structure of the light-receiving-side optical system may be changed, as appropriate. For example, a structure in which a plurality of lenses are used or a structure in which a mirror is disposed in the middle of the optical path may be adopted.
(7) The order in which steps in processing are executed in the embodiment is an example for specifically describing the present invention, and an order other than the order above may be adopted. Furthermore, some of the steps in processing may be executed at the same time as (in parallel with) other steps.
Furthermore, at least some of the functions in the embodiments and the modifications thereof may be combined with one another.
The embodiments described above each indicate one preferred specific example of the present invention. The numerical values, the shapes, the materials, the constituent elements, the positions of arrangement and connections of constituent elements, the processes, the order of processes, etc., indicated in the embodiments are examples, and are not intended to limit the present invention. Furthermore, among the constituent elements in the embodiments, those that are not recited in the independent claims, which represent the highest-level concepts of the present invention, are described as optional constituent elements constituting preferred embodiments.
Furthermore, the order according to which the above-described method is executed is an example for specifically describing the present invention, and an order other than the order above may be adopted. Furthermore, parts of the above-described method may be performed at the same time as (in parallel with) other methods.
Furthermore, in order to facilitate understanding of the invention, constituent elements in the drawings mentioned in the embodiments are not necessarily drawn to scale. Furthermore, the present invention is not limited by the description of the above embodiments, and can be modified, as appropriate, within the scope of the present invention.
Furthermore, all numbers used above are examples for specifically describing the present invention, and the present invention is not limited by the numbers used as examples.
The substance-in-blood concentration measurement device and the substance-in-blood concentration measurement method according to aspects of the present disclosure can be widely used in medical devices for the daily measurement of states of substances in blood, such as the blood sugar level and blood lipid level, in the prevention and treatment of lifestyle-related diseases.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2022/034859 | 9/17/2022 | WO |
